JP2011524360A - Rna単離のための細胞溶解試薬 - Google Patents
Rna単離のための細胞溶解試薬 Download PDFInfo
- Publication number
- JP2011524360A JP2011524360A JP2011513650A JP2011513650A JP2011524360A JP 2011524360 A JP2011524360 A JP 2011524360A JP 2011513650 A JP2011513650 A JP 2011513650A JP 2011513650 A JP2011513650 A JP 2011513650A JP 2011524360 A JP2011524360 A JP 2011524360A
- Authority
- JP
- Japan
- Prior art keywords
- reagent
- rna
- cellular material
- acid
- alkali metal
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003153 chemical reaction reagent Substances 0.000 title claims abstract description 71
- 238000002123 RNA extraction Methods 0.000 title description 6
- 230000006037 cell lysis Effects 0.000 title description 2
- 230000001413 cellular effect Effects 0.000 claims abstract description 18
- 239000000463 material Substances 0.000 claims abstract description 18
- 239000002738 chelating agent Substances 0.000 claims abstract description 11
- 239000003638 chemical reducing agent Substances 0.000 claims abstract description 11
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 claims abstract description 10
- 229960002897 heparin Drugs 0.000 claims abstract description 9
- 229920000669 heparin Polymers 0.000 claims abstract description 9
- 229910001508 alkali metal halide Inorganic materials 0.000 claims abstract description 8
- 150000008045 alkali metal halides Chemical class 0.000 claims abstract description 8
- 239000000872 buffer Substances 0.000 claims abstract description 6
- 239000003960 organic solvent Substances 0.000 claims abstract description 6
- 239000003599 detergent Substances 0.000 claims description 15
- 238000000034 method Methods 0.000 claims description 13
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 12
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical group OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 claims description 10
- 108090000623 proteins and genes Proteins 0.000 claims description 7
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 claims description 7
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 6
- 102000004169 proteins and genes Human genes 0.000 claims description 6
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 claims description 5
- 239000006228 supernatant Substances 0.000 claims description 5
- 239000007983 Tris buffer Substances 0.000 claims description 4
- DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 claims description 4
- XNGIFLGASWRNHJ-UHFFFAOYSA-N phthalic acid Chemical compound OC(=O)C1=CC=CC=C1C(O)=O XNGIFLGASWRNHJ-UHFFFAOYSA-N 0.000 claims description 4
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 claims description 4
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 claims description 3
- PZBFGYYEXUXCOF-UHFFFAOYSA-N TCEP Chemical compound OC(=O)CCP(CCC(O)=O)CCC(O)=O PZBFGYYEXUXCOF-UHFFFAOYSA-N 0.000 claims description 3
- OWMVSZAMULFTJU-UHFFFAOYSA-N bis-tris Chemical compound OCCN(CCO)C(CO)(CO)CO OWMVSZAMULFTJU-UHFFFAOYSA-N 0.000 claims description 3
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 claims description 3
- 229960004889 salicylic acid Drugs 0.000 claims description 3
- 239000011780 sodium chloride Substances 0.000 claims description 3
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 claims description 3
- 239000005725 8-Hydroxyquinoline Substances 0.000 claims description 2
- 102000004190 Enzymes Human genes 0.000 claims description 2
- 108090000790 Enzymes Proteins 0.000 claims description 2
- 239000007995 HEPES buffer Substances 0.000 claims description 2
- FRCAFNBBXRWXQA-XRIGFGBMSA-N L-Histidinol dihydrochloride Chemical compound Cl.Cl.OC[C@@H](N)CC1=CN=CN1 FRCAFNBBXRWXQA-XRIGFGBMSA-N 0.000 claims description 2
- 229910001514 alkali metal chloride Inorganic materials 0.000 claims description 2
- 125000002091 cationic group Chemical group 0.000 claims description 2
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims description 2
- 229960003540 oxyquinoline Drugs 0.000 claims description 2
- MCJGNVYPOGVAJF-UHFFFAOYSA-N quinolin-8-ol Chemical compound C1=CN=C2C(O)=CC=CC2=C1 MCJGNVYPOGVAJF-UHFFFAOYSA-N 0.000 claims description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 claims 2
- KWGKDLIKAYFUFQ-UHFFFAOYSA-M lithium chloride Chemical compound [Li+].[Cl-] KWGKDLIKAYFUFQ-UHFFFAOYSA-M 0.000 claims 2
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 claims 1
- 238000010438 heat treatment Methods 0.000 claims 1
- 235000011164 potassium chloride Nutrition 0.000 claims 1
- 239000001103 potassium chloride Substances 0.000 claims 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 22
- 210000004027 cell Anatomy 0.000 description 13
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 8
- -1 poly (oxyethylene) ethanol Chemical class 0.000 description 7
- 238000000605 extraction Methods 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 239000000203 mixture Substances 0.000 description 5
- 239000006172 buffering agent Substances 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- RWSOTUBLDIXVET-UHFFFAOYSA-N Dihydrogen sulfide Chemical class S RWSOTUBLDIXVET-UHFFFAOYSA-N 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- 210000003855 cell nucleus Anatomy 0.000 description 2
- GVGUFUZHNYFZLC-UHFFFAOYSA-N dodecyl benzenesulfonate;sodium Chemical compound [Na].CCCCCCCCCCCCOS(=O)(=O)C1=CC=CC=C1 GVGUFUZHNYFZLC-UHFFFAOYSA-N 0.000 description 2
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- PHTQWCKDNZKARW-UHFFFAOYSA-N isoamylol Chemical compound CC(C)CCO PHTQWCKDNZKARW-UHFFFAOYSA-N 0.000 description 2
- 238000003757 reverse transcription PCR Methods 0.000 description 2
- 229940080264 sodium dodecylbenzenesulfonate Drugs 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
- CWGFSQJQIHRAAE-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol tetrahydrochloride Chemical compound Cl.Cl.Cl.Cl.OCC(N)(CO)CO CWGFSQJQIHRAAE-UHFFFAOYSA-N 0.000 description 1
- 101710159080 Aconitate hydratase A Proteins 0.000 description 1
- 101710159078 Aconitate hydratase B Proteins 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical class OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 102000044126 RNA-Binding Proteins Human genes 0.000 description 1
- 101710105008 RNA-binding protein Proteins 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 230000027455 binding Effects 0.000 description 1
- 230000003196 chaotropic effect Effects 0.000 description 1
- 230000009920 chelation Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- YQOKLYTXVFAUCW-UHFFFAOYSA-N guanidine;isothiocyanic acid Chemical compound N=C=S.NC(N)=N YQOKLYTXVFAUCW-UHFFFAOYSA-N 0.000 description 1
- 239000000383 hazardous chemical Substances 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910000160 potassium phosphate Inorganic materials 0.000 description 1
- 235000011009 potassium phosphates Nutrition 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000003161 ribonuclease inhibitor Substances 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicon dioxide Inorganic materials O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000167 toxic agent Toxicity 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1003—Extracting or separating nucleic acids from biological samples, e.g. pure separation or isolation methods; Conditions, buffers or apparatuses therefor
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Crystallography & Structural Chemistry (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Saccharide Compounds (AREA)
Abstract
【選択図】なし
Description
本出願は2008年6月13日に出願された米国仮特許出願第61/061,159号の利益を主張し、その内容は参照により本願明細書に引用されたものとする。
Claims (18)
- 細胞物質からRNAを抽出するための試薬であって、
(a)約1pg/μL〜約10 pg/μLのヘパリン;
(b)細胞タンパク質のジスルフィド結合を還元するのに効果的な約1mM〜約10mMの還元剤;
(c)RNA二次及び三次構造を破壊するのに十分な量のキレート剤;
(d)トリス塩基、トリス-HCl、ビス-トリス塩基、ビス-トリス-HCl及びHEPESからなる群より選ばれる約1mM〜約100mMの緩衝剤;及び
(e)約1mM〜約100mMのアルカリ金属ハロゲン化物
を含む試薬。 - 前記ヘパリンが前記試薬の約1 pg/μL〜約3 pg/μLを構成する請求項1記載の試薬。
- 前記還元剤が前記試薬の約1mM〜約5mMを構成する請求項1記載の試薬。
- 前記還元剤がジチオスレイトール、β-メルカプトエタノール及びトリス(2-カルボキシ-エチル)ホスフィンからなる群より選ばれるメンバーである請求項1記載の試薬。
- 前記キレート剤がエチレンジアミン四酢酸;エチレングリコール四酢酸;クエン酸;サリチル酸;エチレンジアミン四酢酸、エチレングリコール四酢酸、クエン酸及びサリチル酸の塩;フタル酸;ヒスチジン;ヒスチジノール二塩酸塩;及び8-ヒドロキシキノリンからなる群より選ばれるメンバーである請求項1記載の試薬。
- 前記キレート剤がエチレンジアミン四酢酸である請求項1記載の試薬。
- 前記キレート剤が前記試薬の約0.3mM〜約3mMを構成する請求項1記載の試薬。
- 前記緩衝剤が、前記試薬のpHを約7.5〜約8.0に維持する前記試薬の量を構成する請求項1記載の試薬。
- 前記アルカリ金属ハロゲン化物が塩化ナトリウム、塩化カリウム及び塩化リチウムからなる群より選ばれる請求項1記載の試薬。
- 前記アルカリ金属ハロゲン化物がアルカリ金属塩化物であり、前記試薬の約10mM〜約50mMを構成する請求項1記載の試薬。
- 非イオン性洗剤を約2.5%以下の容量で更に含む請求項1記載の試薬。
- 前記試薬が陽イオン洗剤及び陰イオン洗剤を欠く請求項1記載の試薬。
- 細胞物質からRNAを抽出する方法であって、前記細胞物質を請求項1の試薬に前記RNAを上清に十分抽出できる程度に接触させ、前記細胞物質の残りから前記上清を回収することを含む方法。
- 有機溶媒で前記上清を抽出することなく行われる請求項13記載の方法。
- 酵素で前記細胞物質を処理してそこからゲノムDNAを除去することなく行われる請求項13記載の方法。
- 前記細胞物質を熱してそこにあるタンパク質を変性させることなく行われる請求項13記載の方法。
- 前記ヘパリンが前記試薬の約1pg/μL〜約3pg/μLを構成し、前記還元剤が前記試薬の約1mM〜約5mMを構成し、前記キレート剤がエチレンジアミン四酢酸であり、前記試薬の約0.3mM〜約3mMを構成し、前記緩衝剤が前記の試薬のpHを約7.5〜約8.0に維持する前記試薬の量を構成し、前記アルカリ金属ハロゲン化物が前記試薬の約10mM〜約50mMを構成する請求項13記載の方法。
- 前記試薬が非イオン性洗剤を約2.5%以下の容量で更に含み、イオン性洗剤を欠く請求項13記載の方法。
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US6115908P | 2008-06-13 | 2008-06-13 | |
US61/061,159 | 2008-06-13 | ||
US12/479,484 US8357672B2 (en) | 2008-06-13 | 2009-06-05 | Cell lysis reagent for isolation of RNA |
US12/479,484 | 2009-06-05 | ||
PCT/US2009/046832 WO2009152204A1 (en) | 2008-06-13 | 2009-06-10 | Cell lysis reagent for isolation of rna |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2011524360A true JP2011524360A (ja) | 2011-09-01 |
JP5426668B2 JP5426668B2 (ja) | 2014-02-26 |
Family
ID=41417100
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2011513650A Active JP5426668B2 (ja) | 2008-06-13 | 2009-06-10 | Rna単離のための細胞溶解試薬 |
Country Status (5)
Country | Link |
---|---|
US (1) | US8357672B2 (ja) |
EP (1) | EP2300488B1 (ja) |
JP (1) | JP5426668B2 (ja) |
CA (1) | CA2728232C (ja) |
WO (1) | WO2009152204A1 (ja) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9447409B2 (en) * | 2009-09-16 | 2016-09-20 | Life Technologies Corporation | Lysis buffers for extracting nucleic acids |
US9057673B2 (en) * | 2012-08-24 | 2015-06-16 | The Board Of Trustees Of The Leland Stanford Junior University | Method of preparing RNA from ribonuclease-rich sources |
US10436680B2 (en) | 2013-10-15 | 2019-10-08 | Kianoosh Peyvan | Capture, disruption, and extraction apparatus and method |
CN116083530A (zh) | 2016-01-29 | 2023-05-09 | 普瑞珍生物***公司 | 用于核酸纯化的等速电泳 |
AU2018312570B2 (en) | 2017-08-02 | 2024-01-11 | Purigen Biosystems, Inc. | Systems, devices, and methods for isotachophoresis |
WO2019116234A1 (en) | 2017-12-12 | 2019-06-20 | Nestec S.A. | Methods for determining microbiome ribosomal rna composition changes |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2000507108A (ja) * | 1996-03-22 | 2000-06-13 | ゼネカ リミテッド | ナタネ由来のシステインプロテアーゼプロモーターおよび植物胚形質の封じ込めのための方法 |
JP2001252100A (ja) * | 2000-03-09 | 2001-09-18 | Internatl Reagents Corp | 核酸の分別手段 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS58116498A (ja) * | 1981-12-28 | 1983-07-11 | Takeda Chem Ind Ltd | Il‐2をコードする新規伝令rnaの製造法 |
US5128247A (en) | 1989-08-14 | 1992-07-07 | Board Of Regents, The University Of Texas System | Methods for isolation of nucleic acids from eukaryotic and prokaryotic sources |
US20040091923A1 (en) * | 1993-07-23 | 2004-05-13 | Bio-Rad Laboratories, Inc. | Linked linear amplification of nucleic acids |
US6875857B2 (en) * | 2001-01-16 | 2005-04-05 | Invitrogen Corporation | Reagent for the isolation of RNA |
US7745180B2 (en) * | 2002-04-24 | 2010-06-29 | Hitachi Chemical Co., Ltd. | Device and method for high-throughput quantification of mRNA from whole blood |
US20070015165A1 (en) | 2005-07-13 | 2007-01-18 | Sigma-Aldrich Co. | Method for the isolation of RNA from biological sources |
US20080003574A1 (en) * | 2006-06-28 | 2008-01-03 | Sigma-Aldrich Co. | Kits for RNA extraction |
-
2009
- 2009-06-05 US US12/479,484 patent/US8357672B2/en active Active
- 2009-06-10 EP EP09763494.3A patent/EP2300488B1/en active Active
- 2009-06-10 WO PCT/US2009/046832 patent/WO2009152204A1/en active Application Filing
- 2009-06-10 JP JP2011513650A patent/JP5426668B2/ja active Active
- 2009-06-10 CA CA2728232A patent/CA2728232C/en active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2000507108A (ja) * | 1996-03-22 | 2000-06-13 | ゼネカ リミテッド | ナタネ由来のシステインプロテアーゼプロモーターおよび植物胚形質の封じ込めのための方法 |
JP2001252100A (ja) * | 2000-03-09 | 2001-09-18 | Internatl Reagents Corp | 核酸の分別手段 |
Non-Patent Citations (1)
Title |
---|
JPN6013019959; Krawczyk Z et al: Analytical Biochemistry Vol.165, 1987, p.20-27 * |
Also Published As
Publication number | Publication date |
---|---|
JP5426668B2 (ja) | 2014-02-26 |
EP2300488B1 (en) | 2014-03-19 |
EP2300488A4 (en) | 2012-04-04 |
US20090317894A1 (en) | 2009-12-24 |
CA2728232A1 (en) | 2009-12-17 |
EP2300488A1 (en) | 2011-03-30 |
WO2009152204A1 (en) | 2009-12-17 |
US8357672B2 (en) | 2013-01-22 |
CA2728232C (en) | 2014-09-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10087439B1 (en) | Rapid methods for the extraction of nucleic acids from biological samples | |
US7001724B1 (en) | Compositions, methods, and kits for isolating nucleic acids using surfactants and proteases | |
JP5426668B2 (ja) | Rna単離のための細胞溶解試薬 | |
JP4554080B2 (ja) | 細胞および組織試料中にrnaを保存するための方法および試薬 | |
JP2019062917A (ja) | 核酸を単離及び/又は精製するための溶解、結合及び/又は洗浄試薬 | |
JP5950415B2 (ja) | ワックス包埋サンプルからの核酸抽出 | |
KR20130143677A (ko) | 안정화 시약으로부터 핵산을 정제하기 위한 조성물 및 방법 | |
EP2004822B1 (en) | A method for rapid isolation of rna and a kit thereof | |
JP2009519027A (ja) | 固定組織から生体分子を抽出する方法 | |
AU2001297835A1 (en) | Compositions, methods, and kits for isolating nucleic acids using surfactants and proteases | |
AU2016266805B2 (en) | Composition and method for disrupting tissue material | |
US10464961B2 (en) | Nucleic acid purification | |
WO2020102570A1 (en) | Rna preservation solution and methods of manufacture and use | |
US11078476B2 (en) | Methods and kits for extracting nucleic acids from paraffin embedded samples |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20110223 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20130507 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20130806 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20131029 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20131128 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 Ref document number: 5426668 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |